Bioasis Technologies BIOAF · USD

Its shares trade under the ticker BIOAF. It has been listed since 24 July 2007. In the fiscal year to 28 February 2021, it reported revenue of C$4.1m and net income of C$698,410. At that date it held total assets of C$3.3m and shareholders' equity of C$407,196.

biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Burnaby, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Deborah RathjenExecutive Chairman of the Board, President, Chief Executive Officer, since 2017C$306,657
• Mr. David JenkinsChief Financial OfficerC$107,229
• Mr. John HemeonNon-Executive DirectorC$93,604
• Mr. John CurranNon-Executive Independent DirectorC$93,604
• Dr. Mario SaltarelliNon-Executive Independent DirectorC$93,604
• Mr. David WurzerNon-Executive Independent DirectorC$93,604

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.